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Abstract
Introduction: Alzheimer’s disease brains are characterized by extracellular plaques containing the aggregated
amyloid β42 (Aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. Aβ42 is produced by
sequential processing of the amyloid precursor protein (APP) by β-secretase followed by γ-secretase. Substantial
efforts have been put into developing pharmaceuticals preventing the production or increasing the clearance of
Aβ42. However, treatments inhibiting γ-secretase have proven disappointing due to off-target effects. To circumvent
these effects, γ-secretase modulators (GSMs) have been developed, which rather than inhibiting γ-secretase shift its
preference into producing less aggregation-prone shorter Aβ peptides. Belonging to the same family of proteins as
APP, amyloid-like protein 1 (APLP1) is also a substrate for γ-secretase. Herein we investigated whether the GSM
E2012 affects APLP1 processing in the central nervous system by measuring APLP1 peptide levels in cerebrospinal
fluid (CSF) before and after E2012 treatment in dogs.
Methods: An in-house monoclonal APLP1 antibody, AP1, was produced and utilized for immunopurification of
APLP1 from human and dog CSF in a hybrid immuno-affinity mass spectrometric method. Seven dogs received a
single dose of 20 or 80 mg/kg of E2012 in a randomized cross-over design and CSF was collected prior to and
4, 8 and 24 hours after dosing.
Results: We have identified 14 CSF APLP1 peptides in humans and 12 CSF APLP1 peptides in dogs. Of these, seven
were reproducibly detectable in dogs who received E2012. We found a dose-dependent relative increase of the
CSF peptides APLP1β17, 1β18 and 1β28 accompanied with a decrease of 1β25 and 1β27 in response to E2012
treatment. All peptides reverted to baseline over the time of sample collection.
Conclusion: We show an in vivo effect of the GSM E2012 on the processing of APLP1 which is measurable
in CSF. These data suggest that APLP1 peptides may be used as biomarkers to monitor drug effects of GSMs on
γ-secretase processing in clinical trials. However, this requires further investigation in larger cohorts, including
studies in man.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder and the most prevalent form of dementia
[1]. It is characterized by extracellular plaques, containing
aggregated amyloid-β (Aβ) peptides [2], and intraneuronal
tangles consisting of hyperphosphorylated tau [3]. In the
amyloid cascade hypothesis, it is postulated that there is
an imbalance in the production and/or clearance of Aβ
which is believed to cause a series of events including
microglial activation, oxidative stress, neuronal dysfunc-
tion, formation of tangles and inevitable neurodegenera-
tion [4]. For these reasons, targeting the production of the
aggregation prone and potentially toxic 42 amino acid
residue-long variant of Aβ (Aβ42) has been subject to ex-
tensive research with the aim of developing disease modi-
fying compounds that inhibits or modulates the enzymes
responsible for the formation of Aβ (see elaborating re-
views elsewhere [5–7]).
The amyloid precursor protein (APP) is subjected to
proteolytic processing by three secretases: α-secretase,
β-secretase and γ-secretase. The proteolytic activity of
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α-secretase is likely attributed to the protein disintegrin
and metalloproteinase domain-containing protein 10
(ADAM10) [8]; β-secretase has been identified as β-site
APP-cleaving enzyme (BACE) [9]; whereas γ-secretase is
a multisubunit protein complex consisting of nicastrin
(NCSTN), anterior pharynx-defective 1 (APH-1), prese-
nilin enhancer 2 (PEN2) and the N- and C-terminal
fragments of presenilin 1 or 2 (PS1 or PS2) [10]. Aβ42 is
produced through the amyloidogenic pathway where APP
is cleaved by β-secretase [9] and subsequently by γ-
secretase [11]. Alternatively Aβ42 production is prevented
in the non-amyloidogenic pathway where α-secretase ra-
ther than β-secretase cleaves APP within the Aβ sequence
generating shorter Aβ peptides [12].
Secretases are an appealing target to alter the meta-
bolism of Aβ. However, recent clinical trials where AD
patients were treated with γ-secretase inhibitors failed to
reach their primary clinical endpoints; the cognitive de-
cline was even worse in the treatment arm than in placebo
[13, 14]. A diverse array of transmembrane proteins have
been identified as γ-secretase substrates [15], including
Notch [16, 17], and the problems associated with γ-
secretase inhibitor treatment may be explained by the
physiological functions of these substrates [15].
To overcome the possible negative effects of inhibiting
γ-secretase, γ-secretase modulators (GSMs) have been
developed to shift the production from the amyloidogenic
Aβ42 to less aggregation-prone peptides (e.g., Aβ38) with-
out affecting the release of the intracellular domains of
APP and other γ-secretase substrates such as Notch1, cad-
herins, Erb4 and EphB2 [18]. Thus, these compounds
modulate the cleavage pattern of Aβ without inhibiting,
for example, Notch signaling. The effect of GSMs on APP
processing has previously been shown to be measurable in
vivo in cerebrospinal fluid (CSF) from, for example,
monkeys [19] and guinea pigs [20], where the level of
Aβ42 decreased and Aβ37 or Aβ38 increased [19, 20]. In
agreement with these studies, we recently showed that
dogs treated with the GSM E2012 displayed a distinct shift
in the CSF Aβ peptide pattern with decreased levels of
Aβ42 as well as Aβ39 and Aβ40 accompanied with in-
creased levels of Aβ37 [21]. The effects of different GSMs
on Aβ production have been summarized in a review by
Crump et al. [22].
Amyloid-like protein 1 (APLP1) and APP share, to a
large extent, similar structural domains and are both
suggested to be involved in neurite outgrowth, cell adhe-
sion and neuronal migration [23]. APLP1 and APP are
also known to form heterodimers with possible implica-
tions in cell adhesion and synaptogenesis [24, 25]. APLP1
has been suggested to be processed by the same enzymatic
activities as APP including γ-secretase and α-secretase, gen-
erating a p3-like peptide called ALP-1 [24, 26], similar to
the putative p3 fragment identified as a possible proteolytic
product from APP [27]. While it is established that γ-
secretase is responsible for the C-terminal processing
of APLP1 [28–30], the secretase cleaving at the N-
terminus has been suggested to be either α- [26] or β-
secretase [28, 31].
Recently, it was shown that APLP is processed into
short Aβ-like peptides (APLP1β25, 1β27 and 1β28) [28]
and that the concentrations of CSF APLP1β25 and 1β27
were decreased while the concentration of CSF APLP1β28
was unchanged in four different PS1 mutation carriers
[32] leading to an increased APLP1β28 to total APLP1β
ratio [28]. In addition, cells treated with the Aβ42 raising
GSM S2474, or cells harboring certain PS1 mutations
were also found to have an increased APLP1β28 to total
APLP1β ratio and it was suggested that this ratio may
reflect the Aβ42 production in the brain [28]. However,
how the S2474 treatment or PS1 mutations affected the
APLP1β28 concentrations were not reported. Whether
APLP1 peptides can be used as CSF AD biomarkers re-
flecting Aβ42 production needs to be investigated in large
clinical studies, including early clinical stage of AD, AD
dementia and control subjects, in which other CSF and
imaging biomarkers are included.
In order to characterize APLP1 in CSF, we developed a
monoclonal antibody directed against APLP1. We then
used hybrid immuno-affinity-based enrichment of CSF
APLP1 peptides from dogs followed by mass spectrometry
(MS) analysis. In the present study we tested the hypoth-
esis that peptides derived from APLP1 can be used as




The γ-secretase modulator E2012 (cas no. 870843-42-8,
(3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-piperidi-
none) was synthesized according to the described proced-
ure [33].
Experimental animals
Beagle dogs were given a single oral dose of 20 and
80 mg/kg E2012 with a dosing interval of at least 1 week.
The animals were exposed in a randomized cross-over
study as previously described [21]. The animals (seven
males, age 6–8 years) received the compound with a liquid
meal between 7 and 8 am and 1 ml CSF was collected
prior to the meal and 4, 8 and 24 hours after dosing. The
meal consisted of 120 ml concentrated liquid (Convales-
cence support, one satchel dissolved in 112.5 ml warm
water; Crown Pet Foods Ltd., Castle Cary, UK) to which
the compounds had been added directly before feeding.
CSF was collected from awake animals from the lateral
ventricle via a cannula. The CSF was collected into
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polypropylene tubes, immediately placed on dry ice and
stored at −80 °C until analysis. The method for implanting
and collecting CSF via the cannula in dogs has been de-
scribed elsewhere [34]. In brief, a hole was drilled in the
cranium of the dogs into which the cannula was screwed.
The cannula was positioned at the following coordinates:
38–40 mm rostral to the occipital protuberance and 8 mm
lateral to the center of the sagittal crest. The study was con-
ducted according to protocol 2009-252-SD MECHPHA,
approved by the Ethical Committee on Laboratory Animal
Testing (Ethische Commissie Dierproeven, Johnson &
Johnson Pharmaceutical Research and Development,
Beerse, Belgium).
Generation of anti-APLP1 antibody
A monoclonal antibody against APLP1, named AP1, was
generated by immunization of 8-week-old Balb/c mice with
the KLH-conjugated peptide APLP1 (amino acid 568–579,
[UniProtKB:P51693]; Caslo ApS, Lyngby, Denmark) in
complete Freund’s adjuvant (Sigma-Aldrich Co., St Louis,
MO, USA). After three dosages (approximately 75 μg/
mouse), the spleen was removed and B cells were fused
with the myeloma cell line SP2/0 following standard pro-
cedure. Approximately 10 days after fusion, cell media
were screened for APLP1 antibodies using APLP1 full
length and neurogranin (Caslo ApS) as a negative control.
Clones which reacted with the APLP1 protein were further
grown, subcloned and subsequently frozen in liquid nitro-
gen. The isotype was determined using a commercially
available kit (Pierce Rapid Isotyping Kit-Mouse; Thermo
Fisher Scientific Inc., Waltham, MA, USA). Finally, anti-
bodies were purified using a protein G column (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden).
Immuno-affinity mass spectrometry
CSF collected prior to dosing and 4, 8 and 24 hours after
dosing with 20 or 80 mg/kg E2012 was analyzed by hy-
brid immuno-affinity MS as described previously with
some modifications [21]. In brief, 4 μg of the in-house
developed mouse monoclonal anti-APLP1 antibody AP1
was incubated with 25 μl magnetic beads conjugated to
sheep anti-mouse IgG (Dynabeads M280, Invitrogen,
Thermo Fisher Scientific Inc.). Beads with the AP1 anti-
body complex were then washed in phosphate-buffered
saline and added to 600 μl CSF containing 0.0025 %
Tween, to a total volume of 625 μl. CSF with added
beads was incubated over night at +8 °C on a rocking
platform. Elution of APLP1 was performed in a five-step
procedure using a KingFisher mL Magnetic Particle
Processors system (Thermo Fisher Scientific Inc.). The
eluate was dried and redissolved in 5 μl 0.1 % formic
acid in 20 % acetonitrile. The sample in solution was
mixed in a 2:1 ratio with a sample matrix containing
15 g/l alpha-cyano-4-hydroxycinnamic acid and 0.1 %
trifluoroacetic acid in acetonitrile and spotted on an MTP
384 target plate polished steel TF (Bruker Daltonics
GmbH, Bremen, Germany) with a seed layer containing
20 g/l alpha-cyano-4-hydroxycinnamic acid in 10 % me-
thanol and 90 % acetone. The samples were analyzed as
duplicates by matrix-assisted laser desorption ionization
time-of-flight/time-of-flight (MALDI-TOF/TOF) using an
UltrafleXtreme (Bruker Daltonics GmbH) mass spectrom-
eter operating at positive reflector mode. The sample
spectra acquired were processed using flexAnalysis v3.3
(Bruker Daltonics GmbH) by performing baseline subtrac-
tion, smoothening and internal calibration based on the
theoretical monoisotopic masses of APLP1 fragments
1β17 (1615.79m/z), 1β18 (1728.88m/z), 1β22 (2143.11m/
z), 1β25 (2328.19m/z), 1β27 (2472.24m/z) and 1β28
(2585.32m/z). Exported peak lists were subjected to pro-
cessing by an in-house MATLAB (Mathworks Inc.,
Natick, Massachusetts, USA) program which, in short,
relative to the monoisotopic peak, integrated the peak
areas within the limits of −2 to +5m/z. Following this, the
integrated peak areas in each specific spectrum were nor-
malized as the percentage of the total area of all peaks
measured. Duplicate measurements were averaged and
then a fold-change was calculated for samples acquired at
4, 8 and 24 hours against the sample collected prior to
dosing as baseline.
Tandem mass spectrometric identification of peptides
Employing collision-induced dissociation and the LIFT
technology of the UltrafleXtreme, tandem MS (MS/MS)
spectra of selected APLP1 peptides were acquired. These
were processed and annotated in the BioTools software
v3.2 (Bruker Daltonics GmbH) by employing an in-house
Mascot Deamon server (v2.3.2; Matrix Science Ltd.
London, UK) search against an in-house designated
APLP1 [UniProtKB:P51693] database. The parameters for
searching the database were set to singly charged ions,
variable methionine oxidation, a mass tolerance of
200 ppm, MS/MS tolerance of 0.5 Da and a MALDI-TOF/
TOF instrumentation. MS and MS/MS spectra were also
acquired from human CSF using the same sample prepar-
ation methodology as described above. CSF samples were
supplied by clinical routine at the Clinical Neurochemistry
Laboratory, The Sahlgrenska University Hospital, Mölndal,
Sweden, in accordance with ethical approval from the re-
gional ethics committee at the University of Gothenburg.
The samples were de-identified by pooling.
Statistical analysis
Statistical analysis was performed using GraphPad
PRISM v6.04 (GraphPad Software, Inc., San Diego, USA)
comparing the fold-change within each of the doses for
the indicated peptides with Friedman test and employing
Dunn’s test for correction of multiple comparisons.
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Significant results were considered differences with a
calculated p-value of <0.05.
Results
Identification of APLP1 peptides in CSF
By combing the selectivity of the in-house mouse mono-
clonal antibody, AP1, and MS, we here for the first time
show that several APLP1 derived peptides may be used
as biomarkers for target engagement of the GSM E2012
in vivo.
The amino acid sequence for APLP1 for Canis famil-
iaris and Homo sapiens has a 100 % homology [Uni-
protKB:J9JHP8 versus UniprotKB:P51693]. In total, 14
APLP1 peptides were identified in human CSF and 12 in
dog CSF of which nine were confirmed by MS/MS (see
Fig. 1 and Tables 1 and 2 for all identified peptides). All
confirmed peptides started with the aspartic acid found at
amino acid 568 of APLP1 [UniprotKB:P51693] and
included peptides ranging between APLP1β13 up to
APLP1β28. An additional peak that had the mass of the
peptide plus 16 Da, corresponding to oxidation of methio-
nine at position 21, was also observed for several of the
APLP peptides (Fig. 1). Fragment ion mass spectra used
for the identification of APLP1β17 and APLP1β28 are
shown in Fig. 2a and b, respectively.
Modulation of APLP1 processing by E2012 in dogs
In total, seven APLP1 peptides were reproducibly de-
tected in all dog CSF samples (APLP1β17, 1β18, 1β21,
1β22, 1β25, 1β27 and 1β28) and their response to treat-
ment with E2012 was further investigated. See Fig. 3 for
representative mass spectra from a dog treated with
80 mg/kg of the GSM E2012.
Four hours after administration of the GSM E2012
(80 mg/kg), we found higher levels of APLP1β17 (p =
0.027) and APLP1β18 (p = 0.016) compared to 8 hours
Fig. 1 Full mass spectrum of APLP1 immunoprecipitated from cerebrospinal fluid. APLP1 was immunoprecipitated from a dog or b human
cerebrospinal fluid and subjected to MALDI-TOF/TOF in which a full mass spectrum was recorded. The peaks corresponding to the APLP1
peptides that have been identified by their corresponding theoretical masses or tandem mass spectrometry are annotated in the spectrum. The
insert shows a magnification of the peaks detected between 1800 and 2250m/z. Additional peaks of +16m/z following APLP1β21 to 1β28
corresponds to oxidation of methionine at position 21. APLP1 Amyloid-like protein 1
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post-treatment. The increases reverted to baseline levels
at 8 hours post-treatment and remained at baseline
levels 24 hours post-treatment (Fig. 4a and b). No signi-
ficant differences were observed for the two peptides
after the 20 mg/kg dose (Fig. 4a and b). After adminis-
tration of 80 mg/kg, the levels of APLP1β25 were signifi-
cantly decreased both at 4 hours (p = 0.0032) and 8 hours
(p = 0.0032) post-treatment (Fig. 4e). The 20 mg/kg dose
showed a similar trend without reaching statistical signi-
ficance (Fig. 4e). APLP1β28 showed a dose-dependent
increase at 8 hours post-treatment which was significant
for 80 mg/kg (p = 0.0032) but not 20 mg/kg (Fig. 4g).
However, the increase at 8 hours was significant relative
to 24 hours post-treatment for both doses (p = 0.0032
and p = 0.047 for 80 mg/kg and 20 mg/kg, respectively;
Fig. 4g).
APLP1β21 and APLP1β22 did not show any significant
deviations from baseline for either of the two doses
(Fig. 4c and d). The level of APLP1β27 showed a trend
towards decreased levels in a dose-dependent manner in
response to treatment but it did not reach statistical sig-
nificance for either of the doses (Fig. 4f ).
Discussion
In the present study, we show that APLP1 in CSF is
present as a variety of short peptides. For the first time we
also demonstrate that the levels of several CSF APLP1
peptides are markedly affected in response to treatment
with the GSM E2012 suggesting that APLP1-derived pep-
tides may be used as biomarkers to prove target engage-
ment for this type of treatments. To our knowledge there
are no studies of the effect of γ-secretase modulators on
APLP1 processing in vivo to date.
Previously, using an explorative proteomics approach,
we identified eight endogenous APLP1 peptides in hu-
man CSF including APLP1β17, 1β18, 1β25 and 1β27
[35]. By employing the targeted approach described
herein we have identified and confirmed the presence of
the previously identified peptides in CSF [28, 35] and
have now extended the list of identified endogenous
APLP1 peptides. A previous report showed an increase
of APLP1β28 relative to the total amount of APLP1 pep-
tides in CSF from AD subjects [28] while we recently
showed that the levels of APLP1β25, 1β27 and 1β28 in





ppm dogs Observed mass
(Da) human
ppm human Annotation
DELAPAGTGVSRE 1300.63 1300.60 −172 1300.63 39 APLP1β13
DELAPAGTGVSREA 1371.66 1371.65 −114 1371.67 20 APLP1β14
DELAPAGTGVSREAVSG 1614.78 1614.78 −8.5 1614.78 −0.058 APLP1β17
DELAPAGTGVSREAVSGL 1727.87 1727.87 13 1727.87 0.12 APLP1β18
DELAPAGTGVSREAVSGLL 1840.95 1840.96 12 1840.95 −8.2 APLP1β19
DELAPAGTGVSREAVSGLLI 1954.04 1954.04 8.5 1954.04 −8.5 APLP1β20
DELAPAGTGVSREAVSGLLIM 2085.08 2085.08 −2.4 2085.08 1.1 APLP1β21
DELAPAGTGVSREAVSGLLIMG 2142.10 2142.10 −7.6 2142.10 −0.46 APLP1β22
DELAPAGTGVSREAVSGLLIMGA 2213.14 – – 2213.13 −13 APLP1β23
DELAPAGTGVSREAVSGLLIMGAG 2270.16 – – 2270.16 8.5 APLP1β24
DELAPAGTGVSREAVSGLLIMGAGG 2327.18 2327.18 3.3 2327.18 1.0 APLP1β25
DELAPAGTGVSREAVSGLLIMGAGGG 2384.20 2384.19 −33 2384.19 −65 APLP1β26
DELAPAGTGVSREAVSGLLIMGAGGGS 2471.23 2471.23 −0.53 2471.23 −0.91 APLP1β27
DELAPAGTGVSREAVSGLLIMGAGGGSL 2584.32 2584.32 0.72 2584.32 0.31 APLP1β28
Full mass spectra of amyloid-like protein 1 (APLP1) immunoprecipitated from dog and human cerebrospinal fluid were acquired by MALDI-TOF/TOF. The Table shows
the amino acid sequences, the observed masses in Da in dogs and human and their deviation from the theoretical peptide mass in ppm for the peptides identified
Table 2 Tandem mass spectrometric identification of APLP1
peptides
Peptide Observed m/z ppm Ion score Expect a/b/y ions
APLP1β14 1372.71 30.4 48 1.6x10-5 –/4/6
APLP1β17 1615.83 23.7 79 1.3x10-8 4/6/11
APLP1β18 1728.91 21.9 65 3.0x10-7 –/8/10
APLP1β19 1842.06 56.7 18 1.7x10-2 –/5/4
APLP1β21 2086.19 48.1 24 3.9x10-3 –/6/–
APLP1β23 2214.14 −2.91 15 3.3x10-2 –/4/–
APLP1β25 2328.51 138 79 1.3x10-8 7/6/11
APLP1β27 2472.31 27.8 100 9.4x10-11 9/5/9
APLP1β28 2585.40 28.3 93 5.3x10-10 9/11/10
The Table shows the peptides that were identified by tandem mass
spectrometry. The acquired fragment mass spectra were used for searching an
in-house Mascot Deamon server containing a designated amyloid-like protein 1
(APLP1) database. Also shown are the observed masses and the deviation from
the theoretical masses in ppm, as well as identification statistics given as the
Mascot Ion Score and Expect value. The number of identified a, b and y ions are
also indicated
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CSF from Down’s syndrome patients are decreased as
compared to healthy controls [36]. However, whether
CSF APLP1β28 can be used as an AD or Down’s syn-
drome biomarker needs to be investigated in large clin-
ical studies.
Of the 12 identified APLP1 peptides in dog CSF, we
show that several are affected in response to treatment
with the GSM E2012 and that some peptides are affected
in a dose-dependent manner as the effect was more pro-
nounced with the higher dose (80 mg/kg). We found
Fig. 2 Fragment ion mass spectra of APLP1 peptides. Fragment mass spectra generated by tandem mass spectrometry of the peptides
a APLP1β17 and b APLP1β28 immunoprecipitated from human cerebrospinal fluid. Shown are the fragment ions annotated as a, b and y ions. The
fragment spectra were used for identification and annotation by searching an in-house designated APLP1 database using a Mascot Daemon server
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Fig. 3 Full mass spectrum of 80 mg/kg γ-secretase modulation effect in dogs. Full mass spectra of APLP1 were acquired by hybrid immuno-affinity
MALDI-TOF/TOF mass spectrometry. The spectra show the relative changes of the APLP1 peptides in cerebrospinal fluid collected from a dog a prior
to dosing with 80 mg/kg of the γ-secretase modulator E2012 and subsequently b 4, c 8 and d 24 hours after dosing. APLP1 Amyloid-like protein 1
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increased relative levels of APLP1β17, 1β18 and 1β28 in
response to treatment accompanied by decreased rela-
tive levels of APLP1β25 and 1β27. The changes in the
levels for all of the peptides seem to revert towards base-
line levels over time. For APLP1β21 and 1β22 we found
no significant difference. These findings suggest that the
modulation of the APLP1 processing affects the production
over the range of peptides present, not only a single peptide
or exclusively shorter or longer peptides. Furthermore, the
transmembrane region of APLP1 ranges from position
581–603. Thus all identified APLP1 peptides, except
APLP1β13, are located within this region and are accessible
for γ-secretase processing.
Previously we have shown that the CSF levels of Aβ37
increases and Aβ42 decreases in dogs treated with the
GSM E2012 [21]. Here we show in the very same mater-
ial that the levels of several APLP1 peptides are affected
in response to E2012 treatment. Thus investigating the
level of APLP1 peptides in GSM treatment trials may be
highly informative and possibly increase our understand-
ing of the mechanistics and dynamics of APLP process-
ing in the disease.
One limitation with the current study is that the epi-
tope of the APLP1 antibody used (AP1) has not been de-
termined. However MS analysis, including MS/MS,
confirms that the peptides studied in the present study
Fig. 4 Modulation of γ-secretase processing of APLP1 in dogs. APLP1 was immunoprecipitated from cerebrospinal fluid collected from dogs prior
to and 4, 8 and 24 hours after receiving 20 and 80 mg/kg of the γ-secretase modulator E2012. Using MALDI-TOF/TOF, full mass spectra were
recorded in which the intensity of the peak corresponding to a peptide was normalized against the intensity of all the peaks measured in the
spectrum. Shown is the percent deviation from the sample collected prior to dosing (baseline) for the peptides a APLP1β17, b APLP1β18, c APLP1β21,
d APLP1β22, e APLP1β25, f APLP1β27 and g APLP1β28. The measurements are shown as the mean (n = 7) with 95 % confidence interval. Significant
dose effects between time intervals were determined using Friedman test combined with Dunn’s test for multiple comparisons and are indicated as
*p < 0.05 and **p < 0.01. APLP1 Amyloid-like protein 1
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indeed are APLP1 derived. It should also be noted that
the ratio between the different endogenous APLP1 pep-
tides detected cannot be interpreted as a direct reflection
of their absolute abundance in the CSF. This is because
the ionization efficiency might be different for the differ-
ent peptides. Phase I trials in man are needed to further
study the potential of CSF APLP1 peptides to verify tar-
get engagement of GSM drug candidates as well as long-
term clinical trials to examine if these biomarkers also
may predict a beneficial clinical treatment effect.
With GSMs, one of the benefits is to avoid the poten-
tial inhibition of processing of non-intended substrates
such as Notch [16, 17] which has been one of the main
concerns when using γ-secretase inhibitors. However,
GSMs have also shown an effect on Notch processing
but in respect to cleavage site preference and not inhib-
ition [37]. How GSMs affect the processing of the sub-
strates is to a large extent unclear. It is likely dependent
on the particular modulator used and the target with
which it interacts [22]. First generation GSMs have been
hypothesized to interact with the substrate, the secre-
tase, or both [22], and it has been further speculated
that, in the instance of modulators targeting the APP and
Aβ sequences, this might affect the processing by adjust-
ing the position of the amino acid sequence in relation to
the membrane [38]. Second-generation GSMs, to which
E2012 belongs, have been shown rather to interact with
the subunits of γ-secretase [22]. Specifically, E2012 has
been indicated to bind to the N-terminal fragment of PS1
in a competitive manner [39, 40].
Conclusions
We have identified a number of APLP1 peptides in
human and dog CSF. Furthermore we have shown that
γ-secretase modulation, using the GSM E2012, affects
APLP1 proteolytic processing in vivo and that this is
reflected in the relative levels of a number of APLP1
peptides. The soluble nature of the APLP1 peptides
[24, 28] and the fact that APLP1 is a γ-secretase sub-
strate, as indicated herein and shown elsewhere [28–30],
suggests that secreted APLP1 fragments may be inform-
ative when investigating γ-secretase cleavage products in
AD. Our findings show that APLP1 peptides can be used
as in vivo biomarkers for E2012 treatment, which may be
translated to other second-generation GSMs.
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